Search

Your search keyword '"Granston, Tanya"' showing total 18 results
Start Over Author "Granston, Tanya"
18 results on '"Granston, Tanya"'

1. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study

Author

Rinella, Mary E., primary, Dufour, Jean-Francois, additional, Anstee, Quentin M., additional, Goodman, Zachary, additional, Younossi, Zobair, additional, Harrison, Stephen A., additional, Loomba, Rohit, additional, Sanyal, Arun J., additional, Bonacci, Martin, additional, Trylesinski, Aldo, additional, Natha, Macky, additional, Shringarpure, Reshma, additional, Granston, Tanya, additional, Venugopal, Aditya, additional, and Ratziu, Vlad, additional

Published
2022
Full Text
View/download PDF

4. Pooled Analyses of Total Symptom Score (TSS) Responses in Patients with Myelofibrosis (MF) Treated with Pacritinib (PAC) Vs Best Available Therapy (BAT) in Phase 3 Studies (PERSIST-1, PERSIST-2)

Author

Mesa, Ruben A., primary, Cervantes, Francisco, additional, Harrison, Claire N., additional, Mead, Adam J., additional, Vannucchi, Alessandro M., additional, Verstovsek, Srdan, additional, Wang, Lixia, additional, Granston, Tanya, additional, and Mascarenhas, John, additional

Published
2018
Full Text
View/download PDF

5. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis

Author

Mascarenhas, John, primary, Hoffman, Ronald, additional, Talpaz, Moshe, additional, Gerds, Aaron T., additional, Stein, Brady, additional, Gupta, Vikas, additional, Szoke, Anita, additional, Drummond, Mark, additional, Pristupa, Alexander, additional, Granston, Tanya, additional, Daly, Robert, additional, Al-Fayoumi, Suliman, additional, Callahan, Jennifer A., additional, Singer, Jack W., additional, Gotlib, Jason, additional, Jamieson, Catriona, additional, Harrison, Claire, additional, Mesa, Ruben, additional, and Verstovsek, Srdan, additional

Published
2018
Full Text
View/download PDF

6. Additional file 1: Table S1. of Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

Author

Srdan Verstovsek, Olatoyosi Odenike, Singer, Jack, Granston, Tanya, Suliman Al-Fayoumi, and H. Deeg

Abstract

Dose adjustment and toxicity management guidelines—non-hematologic toxicities. Table S2 Serious adverse events and deathsa occurring in phase 1 component of the study (n = 43). Table S3 Day 1 pharmacokinetics of pacritinib in the phase 1 part of the study (n = 43). Table S4 Day 15 pharmacokinetics of pacritinib in the phase 1 part of the study (n = 43). Table S5 Percent change from baseline at week 24 for individual and total symptom scores from the Myelofibrosis Quality of Life and Symptom Assessment Tool—phase 2 (efficacy evaluable population). Table S6 Median percent change from baseline in hematologic parameters over time in the phase 2 component of the study (n = 31). Table S7 Serious adverse events and deathsa occurring in the phase 2 component of the study (n = 31). Figure S1 Mean concentration-time profiles of pacritinib when dosed as hydrochloride and citrate salts at a dose of 200 mg. (DOC 296 kb)

Published
2016
Full Text
View/download PDF

7. Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl

Author

Mascarenhas, John, primary, Hoffman, Ronald, additional, Talpaz, Moshe, additional, Gerds, Aaron T., additional, Stein, Brady, additional, Gupta, Vikas, additional, Szoke, Anita, additional, Drummond, Mark, additional, Pristupa, Alexander, additional, Granston, Tanya, additional, Daly, Robert, additional, Dean, James P., additional, Al-Fayoumi, Suliman, additional, Callahan, Jennifer A., additional, Singer, Jack W., additional, Gotlib, Jason, additional, Jamieson, Catriona, additional, Harrison, Claire, additional, Mesa, Ruben, additional, and Verstovsek, Srdan, additional

Published
2016
Full Text
View/download PDF

9. Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): 60 week follow-up of the phase III PERSIST-1 trial.

Author

Mesa, Ruben A., Egyed, Miklos, Szoke, Anita, Suvorov, Aleksandr, Perkins, Andrew, Mayer, Jiri, Ganly, Peter, Schouten, Harry C., Tosi, Patrizia, Farber, Charles Michael, Zachee, Pierre, Scheid, Christof, Dean, James P., Granston, Tanya, Kiladjian, Jean-Jacques, Vannucchi, Alessandro M., Nangalia, Jyoti, Mead, Adam, Harrison, Claire N., Mesa, Ruben A., Egyed, Miklos, Szoke, Anita, Suvorov, Aleksandr, Perkins, Andrew, Mayer, Jiri, Ganly, Peter, Schouten, Harry C., Tosi, Patrizia, Farber, Charles Michael, Zachee, Pierre, Scheid, Christof, Dean, James P., Granston, Tanya, Kiladjian, Jean-Jacques, Vannucchi, Alessandro M., Nangalia, Jyoti, Mead, Adam, and Harrison, Claire N.

Published
2016

11. Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): 60 week follow-up of the phase III PERSIST-1 trial.

Author

Mesa, Ruben A., primary, Egyed, Miklos, additional, Szoke, Anita, additional, Suvorov, Aleksandr, additional, Perkins, Andrew, additional, Mayer, Jiri, additional, Ganly, Peter, additional, Schouten, Harry C., additional, Tosi, Patrizia, additional, Farber, Charles Michael, additional, Zachee, Pierre, additional, Scheid, Christof, additional, Dean, James P., additional, Granston, Tanya, additional, Kiladjian, Jean-Jacques, additional, Vannucchi, Alessandro M., additional, Nangalia, Jyoti, additional, Mead, Adam, additional, and Harrison, Claire N., additional

Published
2016
Full Text
View/download PDF

12. Analysis of Outcomes By Patient Subgroups in Patients with Myelofibrosis Treated with Pacritinib Vs Best Available Therapy (BAT) in the Phase III Persist-1 Trial

Author

Vannucchi, Alessandro M., primary, Mesa, Ruben A., additional, Cervantes, Francisco, additional, Prasad, Ritam, additional, Jakucs, Janos, additional, Elinder, Anna, additional, Recher, Christian, additional, te Boekhorst, Peter A., additional, Knapper, Steven, additional, Somervaille, Tim, additional, Dean, James P., additional, Granston, Tanya, additional, Mead, Adam, additional, and Harrison, Claire N., additional

Published
2015
Full Text
View/download PDF

13. Relationship Between Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HRQoL) and Efficacy in Patients with Myelofibrosis in the Phase III Persist-1 Trial of Pacritinib Vs. Best Available Therapy (BAT)

Author

Mesa, Ruben A., primary, Harrison, Claire N., additional, Cervantes, Francisco, additional, Dean, James P., additional, Wang, Lixia, additional, Granston, Tanya, additional, Yang, Yoojung, additional, Vannucchi, Alessandro M., additional, and Mead, Adam, additional

Published
2015
Full Text
View/download PDF

15. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

Author

Komrokji, Rami S., primary, Seymour, John F., additional, Roberts, Andrew W., additional, Wadleigh, Martha, additional, To, L. Bik, additional, Scherber, Robyn, additional, Turba, Elyce, additional, Dorr, Andrew, additional, Zhu, Joy, additional, Wang, Lixia, additional, Granston, Tanya, additional, Campbell, Mary S., additional, and Mesa, Ruben A., additional

Published
2015
Full Text
View/download PDF

16. Metabolic Syndrome, Diabetes, and Incidence and Progression of Coronary Calcium

Author

Wong, Nathan D., primary, Nelson, Jennifer C., additional, Granston, Tanya, additional, Bertoni, Alain G., additional, Blumenthal, Roger S., additional, Carr, J. Jeffrey, additional, Guerci, Alan, additional, Jacobs, David R., additional, Kronmal, Richard, additional, Liu, Kiang, additional, Saad, Mohammed, additional, Selvin, Elizabeth, additional, Tracy, Russell, additional, and Detrano, Robert, additional

Published
2012
Full Text
View/download PDF

18. Metabolic Syndrome, Diabetes, and Incidence and Progression of Coronary Calcium The Multiethnic Study of Atherosclerosis Study

Author

Wong, Nathan D., Nelson, Jennifer C., Granston, Tanya, Bertoni, Alain G., Blumenthal, Roger S., Carr, J. Jeffrey, Guerci, Alan, Jacobs, David R., Kronmal, Richard, Liu, Kiang, Saad, Mohammed, Selvin, Elizabeth, Tracy, Russell, and Detrano, Robert

Subjects
calcification, diabetes, risk factors, atherosclerosis
Abstract

ObjectivesThis study sought to examine and compare the incidence and progression of coronary artery calcium (CAC) among persons with metabolic syndrome (MetS) and diabetes mellitus (DM) versus those with neither condition.BackgroundMetS and DM are associated with subclinical atherosclerosis as evidenced by CAC.MethodsThe MESA (Multiethnic Study of Atherosclerosis) included 6,814 African American, Asian, Caucasian, and Hispanic adults 45 to 84 years of age, who were free of cardiovascular disease at baseline. Of these, 5,662 subjects (51% women, mean age 61.0 ± 10.3 years) received baseline and follow-up (mean 2.4 years) cardiac computed tomography scans. We compared the incidence of CAC in 2,927 subjects without CAC at baseline and progression of CAC in 2,735 subjects with CAC at baseline in those with MetS without DM (25.2%), DM without MetS (3.5%), or both DM and MetS (9.0%) to incidence and progression in subjects with neither MetS nor DM (58%). Progression of CAC was also examined in relation to coronary heart disease events over an additional 4.9 years.ResultsRelative to those with neither MetS nor DM, adjusted relative risks (95% confidence intervals [CI]) for incident CAC were 1.7 (95% CI: 1.4 to 2.0), 1.9 (95% CI: 1.4 to 2.4), and 1.8 (95% CI: 1.4 to 2.2) (all p < 0.01), and absolute differences in mean progression (volume score) were 7.8 (95% CI: 4.0 to 11.6; p < 0.01), 11.6 (95% CI: 2.7 to 20.5; p < 0.05), and 22.6 (95% CI: 17.2 to 27.9; p < 0.01) for those with MetS without DM, DM without MetS, and both DM and MetS, respectively. Similar findings were seen in analysis using Agatston calcium score. In addition, progression predicted coronary heart disease events in those with MetS without DM (adjusted hazard ratio: 4.1, 95% CI: 2.0 to 8.5, p < 0.01) and DM (adjusted hazard ratio: 4.9 [95% CI: 1.3 to 18.4], p < 0.05) among those in the highest tertile of CAC increase versus no increase.ConclusionsIndividuals with MetS and DM have a greater incidence and absolute progression of CAC compared with individuals without these conditions, with progression also predicting coronary heart disease events in those with MetS and DM.

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results